Tags:BioTechChemicalDevelopmentDrugPlatformResearch
Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.
Location: United States, Massachusetts, Watertown
Member count: 11-50
Total raised: $81M
Founded date: 2019

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
07.12.2022Series A$81M-4biocapita...

Mentions in press and media 4

DateTitleDescriptionCategoryAuthorSource
17.12.20224BIO Capit...Company’s proprietary end-to-e...--4biocapita...
07.12.2022Entact Bio...Launch fueled by syndicate of ...--4biocapita...
06.12.2022Entact Bio...Entact Bio, the company pionee...--brandoncap...
-Entact Bio“Creating new medicines by enh...--fastfounde...